Website
News25/Ratings7
News · 26 weeks38-73%
2025-10-262026-04-19
Mix2790d
- Insider12(44%)
- Other7(26%)
- SEC Filings4(15%)
- Earnings3(11%)
- Leadership1(4%)
Latest news
25 items- PREvolus to Report First Quarter Financial Results on May 4, 2026Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2026 financial results on Monday, May 4, 2026, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic replay
- PRTelix Appoints David Gill as Non-Executive DirectorMELBOURNE, Australia and INDIANAPOLIS, April 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May 11, 20261. Mr. Gill is expected to be appointed as Chair in due course, succeeding Dr. Mark Nelson who will remain on the Board as a NED. Mr. Gill is a life sciences executive with over 35 years' experience in senior general management and financial leadership roles across commercial and clinical-stage biopharmaceutical (including radiopharmaceuticals) and medical device companies. He current
- PREvolus to Participate in the Needham 25th Annual Virtual Healthcare ConferenceEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Needham Virtual Healthcare Conference. The fireside chat will take place on Tuesday, April 14, 2026, at 3:45 PM ET. The fireside chat can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available 90 days after the date of the presentation. About Evolus, Inc. Evolus (NASDAQ:EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of b
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Evolus Inc.SCHEDULE 13G/A - Evolus, Inc. (0001570562) (Subject)
- INSIDERSEC Form 4 filed by Moatazedi David4 - Evolus, Inc. (0001570562) (Issuer)
- INSIDERSEC Form 4 filed by Avelar Rui4 - Evolus, Inc. (0001570562) (Issuer)
- PREvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Evolus, Inc. (NASDAQ:EOLS) a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during March 2026 of an aggregate of 85,516 restricted stock units (RSUs) and 8,635 stock options of the company's common stock to 10 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with grant dates and vesting commencement dates in March 2026 as inducements material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs and options vest
- INSIDERSEC Form 4 filed by Avelar Rui4 - Evolus, Inc. (0001570562) (Issuer)
- INSIDERSEC Form 4 filed by Moatazedi David4 - Evolus, Inc. (0001570562) (Issuer)
- SECEvolus Inc. filed SEC Form 8-K: Leadership Update8-K - Evolus, Inc. (0001570562) (Filer)
- SECSEC Form S-8 filed by Evolus Inc.S-8 - Evolus, Inc. (0001570562) (Filer)
- SECSEC Form 10-K filed by Evolus Inc.10-K - Evolus, Inc. (0001570562) (Filer)
- SECEvolus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - Evolus, Inc. (0001570562) (Filer)
- PREvolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026Total Net Revenue of $90.3 Million for the Fourth Quarter and $297.2 Million for the Full-Year 2025, Representing Growth of 14% and 12% Over the Prior Year Delivered GAAP Operating Income of $4.2 Million for the Fourth Quarter; Non-GAAP Operating Income of $7.1 Million for Q4 2025, Above Prior Guidance Range Full-Year GAAP Operating Expenses of $229.8 Million in 2025; Non-GAAP Operating Expense of $209.7 Million, Within the Company's Guidance Range of $208 Million to $213 Million, with Second Half 2025 Expenses Declining 4% Compared to the First Half, Driving Meaningful Year-Over-Year Operating Leverage in the Second Half 2026 Net Revenue Guidance of $327 Million to $337 Million,
- PREvolus to Participate in The Leerink Partners Global Healthcare ConferenceEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Leerink Partners Global Healthcare Conference in Miami, FL. The fireside chat will take place on Wednesday, March 11, 2026, at 11:20 AM ET. The fireside chat can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available 90 days after the date of the presentation. About Evolus, Inc. Evolus (NASDAQ:EOLS) is a global performance beauty company redefining the aesthetic injectable market for
- INSIDERDirector Stewart Brady was granted 45,559 shares, increasing direct ownership by 51% to 134,188 units (SEC Form 4)4 - Evolus, Inc. (0001570562) (Issuer)
- INSIDERDirector Parschauer Karah Herdman was granted 45,559 shares, increasing direct ownership by 142% to 77,742 units (SEC Form 4)4 - Evolus, Inc. (0001570562) (Issuer)
- INSIDERChief Financial Officer Mitchell Tatjana was granted 121,489 shares, increasing direct ownership by 116% to 226,092 units (SEC Form 4)4 - Evolus, Inc. (0001570562) (Issuer)
- INSIDERDirector White Albert G Iii was granted 45,559 shares, increasing direct ownership by 90% to 95,937 units (SEC Form 4)4 - Evolus, Inc. (0001570562) (Issuer)
- INSIDERDirector Malik Vikram was granted 45,559 shares, increasing direct ownership by 17% to 321,109 units (SEC Form 4)4 - Evolus, Inc. (0001570562) (Issuer)
- INSIDEROfficer Moatazedi David was granted 313,212 shares, increasing direct ownership by 88% to 667,600 units (SEC Form 4)4 - Evolus, Inc. (0001570562) (Issuer)
- INSIDERDirector Gill David N was granted 45,559 shares, increasing direct ownership by 110% to 86,887 units (SEC Form 4)4 - Evolus, Inc. (0001570562) (Issuer)
- INSIDEROfficer Avelar Rui was granted 94,913 shares, increasing direct ownership by 27% to 451,734 units (SEC Form 4)4 - Evolus, Inc. (0001570562) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Evolus Inc.SCHEDULE 13G/A - Evolus, Inc. (0001570562) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Evolus Inc.SCHEDULE 13G/A - Evolus, Inc. (0001570562) (Subject)